Conversion of fully convertible warrants into equity
As filed · Ind-Swift Laboratories Limited has informed the Exchange about Conversion of fully convertible warrants into equity.
What happened
FactInd-Swift Laboratories Limited has informed the Exchange about Conversion of fully convertible warrants into equity. your good office that the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited. Convertible Warrants (“Warrants”), allotted on August 30, 2024, at an issue price of ₹ 121/- each to Zeal Global.
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Ind-Swift Laboratories Limited has informed the Exchange about Conversion of fully convertible warrants into equity.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%